Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Benign Prostatic Hyperplasia
NCT06062875Phase 2Recruiting
- Sponsor
- Endeavor Health
- Start
- Jan 2024
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab in benign prostatic hyperplasia (BPH), sponsored by Endeavor Health. Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT06062875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062875.